Skip to main content
. 2004;6(Suppl 8):S3–S9.

Figure 6.

Figure 6

The overall findings of the Bicalutamide Early Prostate Cancer Program demonstrate that in addition to standard care, bicalutamide resulted in a significant reduction in the risk of objective progression. PSA, prostate-specific antigen; HR, hazard ratio; E, events; CI, confidence interval. Reproduced with permission from See.32